AB-FUBINACA
http://dbpedia.org/resource/AB-FUBINACA an entity of type: Thing
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported. Its use has been linked to hospitalizations and deaths.
rdf:langString
rdf:langString
AB-FUBINACA
xsd:integer
38398587
xsd:integer
1081870167
xsd:integer
20
xsd:integer
1185282
xsd:integer
28537614
xsd:integer
1
xsd:integer
21
rdf:langString
N-[-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[methyl]indazole-3-carboxamide
rdf:langString
Anlage II
rdf:langString
Illegal in China
rdf:langString
Class B
rdf:langString
Schedule I
xsd:integer
4
xsd:integer
2
xsd:integer
58124325
rdf:langString
CC[C@H]C=O
xsd:integer
1
rdf:langString
AKOOIMKXADOPDA-KRWDZBQOSA-N
rdf:langString
I7PZF0KTFK
rdf:langString
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported. Its use has been linked to hospitalizations and deaths.
rdf:langString
Schedule II
rdf:langString
P II
xsd:nonNegativeInteger
9595
xsd:string
1185282-01-2
xsd:string
I7PZF0KTFK
xsd:string
58124325